Start here if you're new
what it is
Cryo-Cell stores newborn stem cell samples and sells the equipment and programs that keep those samples frozen for years.
how it gets paid
Last year Cryo-Cell made $32M in revenue. Annual storage fees was the main engine at $15.0M, or 47% of sales.
why growth slowed
Revenue fell 1.3% last year. A normal quarter is on the order of ~$8M (roughly one-fourth of annual sales), not a figure that rivals the whole company's market cap.
what just happened
The latest quarter printed about $0.17 EPS on revenue near ~$8M—watch the next print to see if that holds.
At a glance
C+ balance sheet — struggling to keep the lights on
35/100 earnings predictability — expect surprises
68.6x trailing p/e — you're paying up for this one
49.9% return on capital — every dollar works hard here
$0.05 fy2024 eps est
xvary composite: 31/100 — weak
What they do
Cryo-Cell stores newborn stem cell samples and sells the equipment and programs that keep those samples frozen for years.
Cryo-Cell has been doing this since 1989 and says it stores more than 240,000 cord blood and cord tissue specimens worldwide. That scale matters because if your family already paid to bank a sample, moving it is painful. First-mover status plus long-term storage relationships give this tiny company a stickier base than its $24M market cap suggests.
How they make money
$32M
annual revenue · their business grew -1.3% last year
Annual storage fees
$15.0M
+1.0%
Processing and enrollment fees
$11.0M
4.0%
Cord tissue and ExtraVault services
$4.0M
+6.0%
Lifespan program and equipment
$2.0M
+8.0%
The products that matter
family stem cell storage
Cord Blood Banking
~$26M storage + enrollment · ~81% of ~$32M FY
this is the company on the revenue bridge: annual storage fees ($15.0M) plus processing and enrollment fees ($11.0M) are ~$26M combined (~81% of ~$32M FY). cord tissue / ExtraVault and equipment lines make up the rest. revenue slipped 1.3% vs. prior year.
core
ancillary preservation offering
ExtraVault
inside $0.2M other revenue
it sits inside the remaining $0.2M of other revenue. in human terms: it may help with customer breadth, but it is not moving the financial story yet.
too small to matter
legacy sample base
Stored Sample Portfolio
240,000+ specimens
the company reports more than 240,000 cord blood and cord tissue specimens stored worldwide. that's the sticky base you bill storage against, even if new enrollment growth is thin.
installed base
Key numbers
68.6x
trailing p/e
P/E → how many years of current earnings you are paying for → so what: you are paying a premium multiple for a company with only 1.5% operating margin.
49.9%
return on capital
Return on capital → profit earned on money invested in the business → so what: the asset base can produce good returns even though the company is tiny.
1.5%
operating margin
Operating margin → profit left after running the business → so what: there is almost no cushion if costs rise or sales soften.
$9M
long-term debt
Debt equals 27% of capital, which is manageable but large enough to matter when the whole company is worth only about $24M.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 4 — safer than 20% of stocks
- price stability 15 / 100
- long-term debt $9M (27% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for CCEL right now.
source: institutional data · return history unavailable
What just happened
latest quarter
Latest quarter: about $0.17 EPS on ~$8M revenue (order-of-magnitude vs ~$32M FY).
Full-year revenue was about $32M, down 1.3% vs. prior year. Any single quarter should sit near one-fourth of that unless filings show a one-off; treat big quarter-over-quarter swings as noise until they repeat.
~$8M
revenue (q)
$0.17
eps
1.5%
operating margin
the check
Annual revenue → the full-year number → so what: ~$32M down 1.3% is the anchor; quarter revenue should not read like a second full year unless filings say otherwise.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is NYSE American delisting for continued listing noncompliance.
med
exchange delisting
Cryo-Cell received a continued listing notice on march 12, 2026 and must submit a remediation plan by april 8, 2026.
if the plan fails, the stock loses main-exchange liquidity. for a ~$24M company, that is not a cosmetic problem.
med
cash burn outrunning market value
the company burned $8M in 2025 against a market cap of roughly $24M. that's about one-third of the equity value gone in a year if nothing changes.
continued burn raises the odds of dilution, balance-sheet stress, or both. the math gets mean fast at this size.
med
birth-rate and competition pressure
the core business depends on families choosing private cord blood banking in a category facing more competition and a weaker demographic backdrop.
that pressure lands directly on the $31.4M processing and storage line, which already makes up 99.4% of revenue.
a failed listing fix would pressure 100% of the stock's exchange liquidity while an $8M annual cash burn bears down on a ~$24M equity value.
source: institutional data · regulatory filings · risk analysis
Pay attention to
deadline
april 8 remediation plan
the company must submit its NYSE American compliance plan by april 8, 2026. this is the near-term event that matters most.
cash
whether burn drops below $8M
one profitable quarter is nice. the real test is whether annual cash burn stops running at roughly $8M.
revenue
storage fees back above the prior run rate
processing and storage fees fell 1.3%. you want to see the core line stabilize before talking about a turnaround.
strategy
whether Celle becomes a real value event
the planned spin-off has been on the board since april 2024. until management shows hard economics, treat it as a maybe.
Analyst rankings
earnings predictability
35 / 100
in human-speak, analysts do not trust the earnings line to show up the same way each quarter.
risk rank
4
that puts it safer than only 20% of stocks in the dataset. translation: this is a higher-risk name, not a defensive one.
source: institutional data
Institutional activity
institutional ownership data for CCEL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive